Ten-Day versus 14-Day Levofloxacin-Containing Triple Therapy for Second-Line Anti-Helicobacter pylori Eradication in Taiwan
Second-line Helicobacter pylori (H. pylori) eradication with fluoroquinolone-containing triple therapy is one of the recommended treatment options, but neither 7-day nor 10-day regimens provide >90% success rates. The current retrospective study aimed to clarify the effects of 10-day and 14-day l...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2013-01-01
|
| Series: | Gastroenterology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2013/932478 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832556162967404544 |
|---|---|
| author | Wei-Chen Tai Chien-Hua Chiu Chih-Ming Liang Kuo-Chin Chang Chung-Mou Kuo Yi-Chun Chiu Keng-Liang Wu Ming-Luen Hu Yeh-Pin Chou Shue-Shian Chiou King-Wah Chiu Chung-Huang Kuo Tsung-Hui Hu Ming-Tsung Lin Seng-Kee Chuah |
| author_facet | Wei-Chen Tai Chien-Hua Chiu Chih-Ming Liang Kuo-Chin Chang Chung-Mou Kuo Yi-Chun Chiu Keng-Liang Wu Ming-Luen Hu Yeh-Pin Chou Shue-Shian Chiou King-Wah Chiu Chung-Huang Kuo Tsung-Hui Hu Ming-Tsung Lin Seng-Kee Chuah |
| author_sort | Wei-Chen Tai |
| collection | DOAJ |
| description | Second-line Helicobacter pylori (H. pylori) eradication with fluoroquinolone-containing triple therapy is one of the recommended treatment options, but neither 7-day nor 10-day regimens provide >90% success rates. The current retrospective study aimed to clarify the effects of 10-day and 14-day levofloxacin-containing triple therapies for second-line H. pylori eradication in a Taiwanese cohort and to evaluate the potential clinical factors influencing eradication. A total of 200 patients who failed H. pylori eradication using the standard triple therapy were prescribed with either a 10-day (EAL-10) or a 14-day (EAL-14) levofloxacin-containing triple therapy group (levofloxacin 500 mg once daily, amoxicillin 1 g twice daily, and esomeprazole 40 mg twice daily). Follow-up studies to assess treatment response were carried out 8 weeks later. Eradication rates attained by EAL-10 and EAL-14 were 75.6%; 95% –85.3% and 92.5%; 95% –98.1%, in the per protocol analysis and 68%; 95% –78.5% and 86%; 95% –93.4%, in the intention-to-treat analysis. The duration of H. pylori therapy is the independent risk factor of H. pylori eradication (). In conclusion, 14-day levofloxacin-containing triple therapy can provide a >90% H. pylori eradication rate, but 10-day treatment duration may be suboptimal. The longer duration of H. pylori therapy (14 days) is the independent risk factor. |
| format | Article |
| id | doaj-art-d4757df789a44ecd882f4338bfa47605 |
| institution | Kabale University |
| issn | 1687-6121 1687-630X |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Gastroenterology Research and Practice |
| spelling | doaj-art-d4757df789a44ecd882f4338bfa476052025-02-03T05:46:15ZengWileyGastroenterology Research and Practice1687-61211687-630X2013-01-01201310.1155/2013/932478932478Ten-Day versus 14-Day Levofloxacin-Containing Triple Therapy for Second-Line Anti-Helicobacter pylori Eradication in TaiwanWei-Chen Tai0Chien-Hua Chiu1Chih-Ming Liang2Kuo-Chin Chang3Chung-Mou Kuo4Yi-Chun Chiu5Keng-Liang Wu6Ming-Luen Hu7Yeh-Pin Chou8Shue-Shian Chiou9King-Wah Chiu10Chung-Huang Kuo11Tsung-Hui Hu12Ming-Tsung Lin13Seng-Kee Chuah14Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, and Chang Gung University College of Medicine, Kaohsiung 833, TaiwanDivision of General Medicine, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung 833, TaiwanDivision of Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, and Chang Gung University College of Medicine, Kaohsiung 833, TaiwanDivision of Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, and Chang Gung University College of Medicine, Kaohsiung 833, TaiwanDivision of Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, and Chang Gung University College of Medicine, Kaohsiung 833, TaiwanDivision of Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, and Chang Gung University College of Medicine, Kaohsiung 833, TaiwanDivision of Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, and Chang Gung University College of Medicine, Kaohsiung 833, TaiwanDivision of Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, and Chang Gung University College of Medicine, Kaohsiung 833, TaiwanDivision of Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, and Chang Gung University College of Medicine, Kaohsiung 833, TaiwanDivision of Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, and Chang Gung University College of Medicine, Kaohsiung 833, TaiwanDivision of Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, and Chang Gung University College of Medicine, Kaohsiung 833, TaiwanDivision of Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, and Chang Gung University College of Medicine, Kaohsiung 833, TaiwanDivision of Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, and Chang Gung University College of Medicine, Kaohsiung 833, TaiwanDivision of Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, and Chang Gung University College of Medicine, Kaohsiung 833, TaiwanDivision of Gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, and Chang Gung University College of Medicine, Kaohsiung 833, TaiwanSecond-line Helicobacter pylori (H. pylori) eradication with fluoroquinolone-containing triple therapy is one of the recommended treatment options, but neither 7-day nor 10-day regimens provide >90% success rates. The current retrospective study aimed to clarify the effects of 10-day and 14-day levofloxacin-containing triple therapies for second-line H. pylori eradication in a Taiwanese cohort and to evaluate the potential clinical factors influencing eradication. A total of 200 patients who failed H. pylori eradication using the standard triple therapy were prescribed with either a 10-day (EAL-10) or a 14-day (EAL-14) levofloxacin-containing triple therapy group (levofloxacin 500 mg once daily, amoxicillin 1 g twice daily, and esomeprazole 40 mg twice daily). Follow-up studies to assess treatment response were carried out 8 weeks later. Eradication rates attained by EAL-10 and EAL-14 were 75.6%; 95% –85.3% and 92.5%; 95% –98.1%, in the per protocol analysis and 68%; 95% –78.5% and 86%; 95% –93.4%, in the intention-to-treat analysis. The duration of H. pylori therapy is the independent risk factor of H. pylori eradication (). In conclusion, 14-day levofloxacin-containing triple therapy can provide a >90% H. pylori eradication rate, but 10-day treatment duration may be suboptimal. The longer duration of H. pylori therapy (14 days) is the independent risk factor.http://dx.doi.org/10.1155/2013/932478 |
| spellingShingle | Wei-Chen Tai Chien-Hua Chiu Chih-Ming Liang Kuo-Chin Chang Chung-Mou Kuo Yi-Chun Chiu Keng-Liang Wu Ming-Luen Hu Yeh-Pin Chou Shue-Shian Chiou King-Wah Chiu Chung-Huang Kuo Tsung-Hui Hu Ming-Tsung Lin Seng-Kee Chuah Ten-Day versus 14-Day Levofloxacin-Containing Triple Therapy for Second-Line Anti-Helicobacter pylori Eradication in Taiwan Gastroenterology Research and Practice |
| title | Ten-Day versus 14-Day Levofloxacin-Containing Triple Therapy for Second-Line Anti-Helicobacter pylori Eradication in Taiwan |
| title_full | Ten-Day versus 14-Day Levofloxacin-Containing Triple Therapy for Second-Line Anti-Helicobacter pylori Eradication in Taiwan |
| title_fullStr | Ten-Day versus 14-Day Levofloxacin-Containing Triple Therapy for Second-Line Anti-Helicobacter pylori Eradication in Taiwan |
| title_full_unstemmed | Ten-Day versus 14-Day Levofloxacin-Containing Triple Therapy for Second-Line Anti-Helicobacter pylori Eradication in Taiwan |
| title_short | Ten-Day versus 14-Day Levofloxacin-Containing Triple Therapy for Second-Line Anti-Helicobacter pylori Eradication in Taiwan |
| title_sort | ten day versus 14 day levofloxacin containing triple therapy for second line anti helicobacter pylori eradication in taiwan |
| url | http://dx.doi.org/10.1155/2013/932478 |
| work_keys_str_mv | AT weichentai tendayversus14daylevofloxacincontainingtripletherapyforsecondlineantihelicobacterpylorieradicationintaiwan AT chienhuachiu tendayversus14daylevofloxacincontainingtripletherapyforsecondlineantihelicobacterpylorieradicationintaiwan AT chihmingliang tendayversus14daylevofloxacincontainingtripletherapyforsecondlineantihelicobacterpylorieradicationintaiwan AT kuochinchang tendayversus14daylevofloxacincontainingtripletherapyforsecondlineantihelicobacterpylorieradicationintaiwan AT chungmoukuo tendayversus14daylevofloxacincontainingtripletherapyforsecondlineantihelicobacterpylorieradicationintaiwan AT yichunchiu tendayversus14daylevofloxacincontainingtripletherapyforsecondlineantihelicobacterpylorieradicationintaiwan AT kengliangwu tendayversus14daylevofloxacincontainingtripletherapyforsecondlineantihelicobacterpylorieradicationintaiwan AT mingluenhu tendayversus14daylevofloxacincontainingtripletherapyforsecondlineantihelicobacterpylorieradicationintaiwan AT yehpinchou tendayversus14daylevofloxacincontainingtripletherapyforsecondlineantihelicobacterpylorieradicationintaiwan AT shueshianchiou tendayversus14daylevofloxacincontainingtripletherapyforsecondlineantihelicobacterpylorieradicationintaiwan AT kingwahchiu tendayversus14daylevofloxacincontainingtripletherapyforsecondlineantihelicobacterpylorieradicationintaiwan AT chunghuangkuo tendayversus14daylevofloxacincontainingtripletherapyforsecondlineantihelicobacterpylorieradicationintaiwan AT tsunghuihu tendayversus14daylevofloxacincontainingtripletherapyforsecondlineantihelicobacterpylorieradicationintaiwan AT mingtsunglin tendayversus14daylevofloxacincontainingtripletherapyforsecondlineantihelicobacterpylorieradicationintaiwan AT sengkeechuah tendayversus14daylevofloxacincontainingtripletherapyforsecondlineantihelicobacterpylorieradicationintaiwan |